CL2016003095A1 - Péptidos como agonistas de la oxitocina - Google Patents

Péptidos como agonistas de la oxitocina

Info

Publication number
CL2016003095A1
CL2016003095A1 CL2016003095A CL2016003095A CL2016003095A1 CL 2016003095 A1 CL2016003095 A1 CL 2016003095A1 CL 2016003095 A CL2016003095 A CL 2016003095A CL 2016003095 A CL2016003095 A CL 2016003095A CL 2016003095 A1 CL2016003095 A1 CL 2016003095A1
Authority
CL
Chile
Prior art keywords
peptides
oxytocin agonists
agonists
oxytocin
oxitocine
Prior art date
Application number
CL2016003095A
Other languages
English (en)
Inventor
Caterina Bissantz
Konrad Bleicher
Christophe Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50842169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016003095A1 publication Critical patent/CL2016003095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>COMPUESTOS DERIVADOS PEPTIDICOS, AGONISTAS DE OXITOCINA; COMPOSICION FARMACEUTICA; Y SU }USO PARA EL TRATAMIENTO DEL AUTISMO, EL ESTRE, ANSIEDAD ENTRE OTROS.</p>
CL2016003095A 2014-06-03 2016-12-01 Péptidos como agonistas de la oxitocina CL2016003095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14170992 2014-06-03

Publications (1)

Publication Number Publication Date
CL2016003095A1 true CL2016003095A1 (es) 2017-06-16

Family

ID=50842169

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003095A CL2016003095A1 (es) 2014-06-03 2016-12-01 Péptidos como agonistas de la oxitocina

Country Status (16)

Country Link
US (1) US9957298B2 (es)
EP (1) EP3151849B1 (es)
JP (1) JP6412170B2 (es)
KR (1) KR20170004013A (es)
CN (1) CN106414479B (es)
AU (1) AU2015270723A1 (es)
CA (1) CA2949173A1 (es)
CL (1) CL2016003095A1 (es)
CR (1) CR20160563A (es)
EA (1) EA030091B1 (es)
IL (1) IL248553A0 (es)
MX (1) MX2016015873A (es)
PE (1) PE20161559A1 (es)
PH (1) PH12016502232A1 (es)
SG (1) SG11201610073PA (es)
WO (1) WO2015185467A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3666258T3 (da) 2014-09-19 2024-02-05 Ferring Bv Fremgangsmåde til behandling af prader-willis syndrom
AU2018340867B2 (en) * 2017-09-28 2021-05-27 Kinoxis Therapeutics Pty Ltd Metabolite inspired selective oxytocin receptor agonists
AU2019345166B2 (en) * 2018-09-20 2021-09-02 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
JP7538802B2 (ja) 2018-09-20 2024-08-22 アカディア ファーマシューティカルズ インコーポレイテッド カルベトシン医薬品およびその製造プロセス

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9701162D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
KR20070022753A (ko) * 2004-05-26 2007-02-27 화이자 인코포레이티드 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
CA2676066C (en) * 2007-01-22 2016-06-28 Gtx, Inc. Nuclear receptor binding agents
CA2718148C (en) * 2008-03-31 2017-11-07 Ferring B.V. Oxytocin analogues
EP2337783A1 (en) * 2008-09-23 2011-06-29 F. Hoffmann-La Roche AG Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors
CN102414204B (zh) * 2009-05-05 2014-12-31 弗·哈夫曼-拉罗切有限公司 异噁唑-哒嗪衍生物
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
ES2509270T3 (es) * 2009-10-01 2014-10-17 The University Of Sydney Terapia y prevención del alcoholismo
RS57690B1 (sr) 2012-12-21 2018-11-30 Hoffmann La Roche Peptidi kao agonisti oksitocina

Also Published As

Publication number Publication date
US20170081369A1 (en) 2017-03-23
WO2015185467A1 (en) 2015-12-10
JP6412170B2 (ja) 2018-10-24
MX2016015873A (es) 2017-03-27
EP3151849B1 (en) 2018-10-10
JP2017518311A (ja) 2017-07-06
EP3151849A1 (en) 2017-04-12
AU2015270723A1 (en) 2016-11-17
EA030091B1 (ru) 2018-06-29
PE20161559A1 (es) 2017-01-12
US9957298B2 (en) 2018-05-01
EA201692404A1 (ru) 2017-05-31
KR20170004013A (ko) 2017-01-10
SG11201610073PA (en) 2016-12-29
CA2949173A1 (en) 2015-12-10
CR20160563A (es) 2017-01-06
CN106414479A (zh) 2017-02-15
CN106414479B (zh) 2021-08-03
IL248553A0 (en) 2016-12-29
PH12016502232A1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015001724A1 (es) Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2017003404A1 (es) Compuestos antibacterianos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2015003735A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2016012446A (es) Derivados de quinoxalina utiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2015002897A1 (es) Inhibidores de bace1
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CU24407B1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CL2018001085A1 (es) Derivados de indolin-2-ona
CL2016003076A1 (es) Péptidos como agonistas de la oxitocina